Drug interactions in transplant patients: what everyone should know.
作者： Wana Manitpisitkul , Erin McCann , Sabrina Lee , Matthew R Weir
DOI: 10.1097/MNH.0B013E32832EDCB2
关键词: Therapeutic index 、 Drug 、 Intensive care medicine 、 Transplant patient 、 Medicine
摘要: Purpose of reviewAdverse events due to drug–drug interactions remain a challenge in the postsurgical care transplant recipients. A combination potent and selective immunosuppressive drugs, which have narrow therapeutic index, with medications for treatment comorbidities such as dyslip
sci-hub.se 参考文章(107)
M.F.A. Woodruff, B. Nolan, J.S. Robson, AnneT. Lambie, T.I. Wilson, J.G. Clark, HOMOTRANSPLANTATION OF KIDNEY IN PATIENTS TREATED BY PREOPERATIVE LOCAL IRRADIATION AND POSTOPERATIVE ADMINISTRATION OF AN ANTIMETABOLITE (IMURAN): Report of Six Cases The Lancet. ,vol. 282, pp. 675- 682 ,(1963) , 10.1016/S0140-6736(63)90465-3
Thomas B. Strouse, Lynn A. Fairbanks, Christine E. Skotzko, Fawzy I. Fawzy, Fluoxetine and cyclosporine in organ transplantation : failure to detect significant drug interactions or adverse clinical events in depressed organ recipients Psychosomatics. ,vol. 37, pp. 23- 30 ,(1996) , 10.1016/S0033-3182(96)71594-3
H. W. SOLLINGER, Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. Transplantation. ,vol. 60, pp. 225- 232 ,(1995) , 10.1097/00007890-199508000-00003
Uwe Christians, Wolfgang Jacobsen, Leslie C. Floren, Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in transplant patients: are the statins mechanistically similar? Pharmacology & Therapeutics. ,vol. 80, pp. 1- 34 ,(1998) , 10.1016/S0163-7258(98)00016-3
Anders ??sberg, Interactions between cyclosporin and lipid-lowering drugs: implications for organ transplant recipients. Drugs. ,vol. 63, pp. 367- 378 ,(2003) , 10.2165/00003495-200363040-00003
Terry E. Jones, Raymond G. Morris, Pharmacokinetic interaction between tacrolimus and diltiazem: dose-response relationship in kidney and liver transplant recipients. Clinical Pharmacokinectics. ,vol. 41, pp. 381- 388 ,(2002) , 10.2165/00003088-200241050-00005
Y Vanrenterghem, H Ekberg, J Grinyo, G Tufveson, C Groth, D Cantarovich, L Mjornstedt, S Sadek, R Pichlmayr, F Moreso, G Gannedahl, P Lang, Adam Tegzess, J Rodicio, van Willem Son, A Morgan, A Tarantino, J Peeters, M Campise, J Lodge, K Hutchinson, J Erhard, K Wagner, L Hooftman, S Carl, G Ligtenberg, G Thiel, R Luck, M Wiesel, M Zeiler, Hh Neumayer, Sa Sadek, Jp Soulillou, K Rigg, B Bourgeon, P Fauchald, Hauser, C Brattstrom, R Hene, M Behrend, D Albrechtsen, N Persson, J Morales, PLACEBO-CONTROLLED STUDY OF MYCOPHENOLATE MOFETIL COMBINED WITH CYCLOSPORINE AND CORTICOSTEROIDS FOR PREVENTION OF ACUTE REJECTION The Lancet. ,vol. 345, pp. 1321- 1325 ,(1995)
Kushari Bowalgaha, John O. Miners, The glucuronidation of mycophenolic acid by human liver, kidney and jejunum microsomes British Journal of Clinical Pharmacology. ,vol. 52, pp. 605- 609 ,(2001) , 10.1046/J.0306-5251.2001.01487.X
P E Nolan, J C Wild, S M Butman, PROSPECTIVE STUDY OF THE SAFETY AND FINANCIAL BENEFIT OF KETOCONAZOLE AS ADJUNCTIVE THERAPY TO CYCLOSPORINE AFTER HEART TRANSPLANTATION Journal of Heart and Lung Transplantation. ,vol. 10, pp. 351- 358 ,(1991)
Kenneth S. Lown, Steven A. Wrighton, Paul B. Watkins, Kenneth E. Thummel, Robert J. Fontana, David G. Bailey, Stephen D. Hall, Stephen D. Hall, Leslie Z. Benet, Mary F. Paine, Robert R. Mayo, D. Kim Turgeon, Molecular and physical mechanisms of first-pass extraction. Drug Metabolism and Disposition. ,vol. 27, pp. 161- 166 ,(1999)